

4DMedical unveils CT:VQ at RSNA 2024

4 December 2024

Highlights

- 4DMedical unveils upcoming ground-breaking product, CT:VQ, at RSNA 2024
- Displacing Nuclear VQ diagnostic imaging represents a \$1 billion market opportunity in the U.S.
- Significant opportunity to improve healthcare equity and accessibility not being addressed by Nuclear VQ diagnostic imaging based on early clinical results

Melbourne, Australia, 4 December 2024: 4DMedical Limited (ASX: 4DX) ("4DMedical" or the "Company"), a leader in respiratory imaging technology, today announces it presented ongoing clinical trial results of its much anticipated ventilation and perfusion technology, CT:VQ, at the Radiological Society of North America Annual Meeting (RSNA 2024) in Chicago.

CT:VQ presentation in the Innovation Theater at RSNA 2024

4DMedical Limited (ASX: 4DX), a leader in advanced lung imaging and analytics, has presented its cutting-edge technology at RSNA 2024, ahead of expected FDA submission in mid 2025. Among the highlights of the event was 4DMedical's impactful presentation on Tuesday, 3 December, conducted in collaboration with Philips, which focused on driving partnerships and innovation in lung health.

The presentation, *"Innovation, Partnerships – for Lung Health and Veterans: Philips and 4DMedical"*, co-hosted by Philips in the Innovation Theater at RSNA 2024, emphasised the synergies between 4DMedical's technologies and Philips' healthcare presence. Together, the companies illustrated how their partnership is enhancing diagnostic precision, streamlining clinical workflows, and broadening access to advanced respiratory care. In addition, the presentation provided the opportunity for both Philips and 4DMedical to emphasise the importance of providing solutions to evaluate Veterans with deployment-related respiratory disease (DRRD), and other significant pulmonary challenges. The session attracted significant attention from healthcare leaders and radiology professionals, who gained insights into the collaborative development of integrated solutions for managing patient care.

During the presentation, 4DMedical was invited to unveil its upcoming ground-breaking CT:VQ technology. This advanced imaging solution offers a compelling alternative to traditional Nuclear VQ scans, providing clinicians with comparable diagnostic insights while eliminating the need for radioactive isotopes and other expensive infrastructure requirements. 4DMedical demonstrated how CT:VQ can deliver superior access to care, faster results, and improved safety for patients. The session, attended by an audience of industry professionals, highlighted the potential for CT:VQ to redefine lung ventilation and perfusion imaging and drive significant advancements in respiratory diagnostics.

More broadly, RSNA 2024 has provided 4DMedical with a platform to demonstrate the transformative capabilities of its product portfolio at its dedicated booth in the South Hall. Live demonstrations have provided attendees with an opportunity to experience the Company's FDA-cleared imaging solutions, which includes the unique four-dimensional visualisation and quantification of lung function alongside our portfolio of structural lung analytics. Visitors have explored how this advanced cardiopulmonary suite, combining imaging with AI-driven analytics, continues to garner recognition for its ability to provide actionable insights to help clinicians make faster, more informed decisions.




Clinical case for CT:VQ

There is a clear and present clinical need for a step change in diagnostic imaging with respect to nuclear medicine. When compared with traditional nuclear medicine VQ diagnostics, CT:VQ offers a clinically equivalent option to current Nuclear VQ diagnostic imaging (see figure below). Clinically, Nuclear VQ scans are primarily used for diagnosing and managing post-acute pulmonary embolism and associated conditions such as pulmonary hypertension, and chronic thromboembolic pulmonary hypertension.

Aside from the difference in the depth of insight provided, CT:VQ has three major advantages over existing Nuclear VQ diagnostic imaging. Firstly, the CT:VQ product developed by 4DMedical offers a faster, more convenient solution, which can be completed in a fraction of the time to acquire a Nuclear VQ scan. Secondly, CT:VQ extracts perfusion and ventilation data without the use of radioactive contrast agents, enabling any hospital with a CT scanner to conduct the test, dramatically improving patient equity through greater accessibility. Finally, CT:VQ is an immediately scalable workflow solution to hospitals and physicians, as it utilizes clinically accepted technology and software compatible with existing hospital CT scanners, enabling rapid adoption.

The U.S. market size for nuclear medicine VQ scans is estimated to be in excess of US\$1 billion, with approximately 1 million tests per year at an average cost of over US\$1,000 per scan. 4DMedical's CT:VQ technology presents an opportunity to displace a cumbersome and inefficient diagnostic tool, as well potentially extending its use through an enhanced patient experience to a much broader audience.



4DMedical MD/CEO and Founder, Andreas Fouras, said:

We are incredibly excited by recent progress we have made with CT:VQ. The Company is well advanced in the completion of its FDA submission which we are targeting for mid 2025. In addition, the recent injection of funding via our successful CRC-P grant will facilitate expansion and acceleration of the clinical evidence required to empower physicians to immediately substitute Nuclear VQ scans for 4DMedical's CT:VQ.



–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity, and more personalised care for patients.

To learn more, please visit www.4dmedical.com